期刊文献+

PLCE1与肺腺癌A549细胞凋亡的相关性及机制研究

STUDY ON THE CORRELATION AND MECHANISM OF PLCE1 AND APOPTOSIS OF LUNG ADENOCARCINOMA A549 CELLS
原文传递
导出
摘要 目的探讨磷脂酶Cε1(PLCE1)表达与肺腺癌A549细胞凋亡的关系及作用机制。方法将肺腺癌细胞株A549分为空白组(仅给予正常培养液)、实验A组(正常培养液+5mmol/L PLCE1抑制剂U73122共培养)、实验B组(正常培养液+10mmol/L PLCE1抑制剂U73122共培养),观察各组,采用流式细胞仪技术检测培养12h、24h及48h时刻A549细胞的凋亡率,采用RT-PCR及Western-blot技术检测各组共培养48h后的PLCE1、p53、Bcl-2、Bax mRNA及蛋白表达水平。结果在培养12h、24h、48h后,实验A组、实验B组的肺腺癌A549细胞凋亡率显著高于空白组(P<0.05);实验B组的肺腺癌A549细胞凋亡率显著高于实验A组(P<0.05);在培养48h后,实验A组、实验B组的p53、Bax mRNA及蛋白水平显著高于空白组(P<0.05),实验A组、实验B组的Bcl-2、PLCE1 mRNA及蛋白水平显著低于空白组(P<0.05);在培养48h后,实验B组的p53、Bax mRNA及蛋白水平显著高于实验A组(P<0.05),实验B组的Bcl-2、PLCE1 mRNA水平显著低于实验A组(P<0.05)。结论通过抑制肺腺癌A549细胞PLCE1的表达,进而抑制上调细胞中p53、Bax表达,下调Bcl-2表达,从而达到促进肺腺癌A549细胞凋亡的目的。 Objective To investigate the relationship between the expression of phospholipase C epsilon 1(PLCE1)and apoptosis of lung adenocarcinoma A549 cells and its mechanism.Methods The lung adenocarcinoma A549 cells were divided into blank group(only given normal medium),experimental group A(normal medium +5 mmol/L PLCE1 inhibitor U73122 co culture),experimental group B(normal medium +10 mmol/L PLCE1 inhibitor U73122 co culture).Apoptosis rate of cultured A549 cells was observed on 12 h,24 h and 48 h using flow cytometry;and on 48 h co cultured,PLCE1,p53,Bcl-2,Bax and mRNA protein expression were detected by RT-PCR and Western-blot technology.Results On 12 h,24 h and 48 h,apoptosis rate of lung adenocarcinoma A549 cells in culture was higher than the control group in the experimental group A and experimental group B(P<0.05);and it was significantly higher in the experimental group B than the experimental group A(P<0.05).After 48 h in culture,p53,Bax mRNA and protein level of the experimental group A and experimental group B was significantly higher than that of the control group(P<0.05),but their Bcl-2,PLCE1 mRNA and protein level was significantly lower than that of the control group(P<0.05);and p53,Bax mRNA and protein level of the experimental group B was also significantly lower than the experimental group A(P<0.05).Conclusion By inhibiting the expression of PLCE1 in lung adenocarcinoma A549 cells,the up regulation of p53 and Bax expression and down regulating the expression of Bcl-2 will be inhibited,so as to promote the apoptosis of lung adenocarcinoma A549 cells.
作者 彭盘俐 吕俊宏 林少欢 蔡长青 Peng Panli;Lv Junhong;Lin Shaohuan(The Second Department of Tumor,The Second Provincial General Hospital of Guandong ,Guangzhou510037,China)
出处 《中国煤炭工业医学杂志》 2018年第6期604-607,共4页 Chinese Journal of Coal Industry Medicine
基金 广东省医学科研基金项目(编号:B2013062)
关键词 磷脂酶Cε1 肺腺癌 凋亡 P53 BCL-2 BAX Phospholipase C epsilon 1 Lung adenocarcinoma Apoptosis p53 Bcl-2 Bax
  • 相关文献

参考文献15

二级参考文献217

  • 1姚珂,向明章,闵家新,张国强,周人杰,李德志.Ⅲ期非小细胞肺癌术前新辅助化疗的随机对照临床试验[J].中国肿瘤临床,2004,31(11):611-613. 被引量:19
  • 2王金万,孙燕,刘永煜,于起涛,张沂平,李凯,朱允中,周清华,侯梅,管忠震,李维廉,庄武,王东林,梁后杰,秦凤展,卢辉山,刘晓晴,孙红,张燕军,王杰军,罗素霞,杨瑞合,涂远荣,王秀问,宋恕平,周静敏,游丽芬,王竞,姚晨.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. 被引量:627
  • 3沈自尹,王文建.中医虚证辨证参考标准[J].中西医结合杂志.1986,6(10):598.
  • 4Kolek V, Grygarkova I, Hajduch M, et al. Long term follow up of neoadjuvant adjuvant combination treatment of ⅢA stage non small cell lung cancer: results of neoadjuvant carboplatin/vinorelbine and carboplatin/paclitaxel regimens combined with selective adjuvant chemotherapy according to in vitro chemoresistance test[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2008, 152: 259 266.
  • 5Depierre A, Milleron B, Moro Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage Ⅰ (except T1N0), Ⅱ, and Ⅲa non small cell lung cancer[J]. J Clin Oncol, 2002, 20: 247 253.
  • 6Mellas N, Elmesbahi O, Masbah O, et al. Neoadjuvant chemotherapy in non small cell lung cancer: current state and future[J]. Bull Cancer, 2010, 97: 211 223.
  • 7Song WA, Zhou NK, Wang W, et al. Survival benefit of neoadjuvant chemotherapy in non small cell lung cancer: an updated meta analysis of 13 randomized control trials[J]. J Thorac Oncol, 2010, 5: 510 516.
  • 8Bozcuk H, Abali H, Coskun S, et al. The correlates of benefit from neoadjuvant chemotherapy before surgery in non small cell lung cancer: a metaregression analysis[J]. World J Surg Oncol, 2012, 10: 161 169.
  • 9Hellmann MD, Chaft JE, William WN, et al. Pathological response after neoadjuvant chemotherapy in resectable non small cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint[J]. Lancet Oncol, 2014, 15: e42 e50.
  • 10Vallières E. More questions about neoadjuvant chemotherapy in lung cancer[J]. Oncology (Williston Park), 2009, 23: 892 896.

共引文献688

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部